Transparency directive : regulatory news

17/05/2018 07:00

17/05/2018 07:00
10/05/2018 11:45
01/05/2018 10:31
23/04/2018 07:00
20/04/2018 12:07
20/04/2018 07:00
17/04/2018 11:45
16/04/2018 11:53
12/04/2018 12:25
12/04/2018 09:28
Vectura Group plc  -  VEC   

AGM Trading Update

Released 07:00 17-May-2018


Vectura Group plc


AGM Trading Update


Chippenham, UK - 17 May 2018: Vectura Group plc (LSE: VEC) ("Vectura" or the "Group"), an industry-leading inhaled product formulation, device design and development business, provides a trading update ahead of its Annual General Meeting ("AGM") being held today at 10.30am at the offices of Clifford Chance LLP, 10 Upper Bank Street, London E14 5JJ.

Based on overall trading performance to date in 2018 the Board confirms that the Group's revenues are in line with its expectations for the full year. Growth in revenues continues to be driven by Vectura's key inhaled marketed products including flutiform® and Ultibro®.

Vectura's Chief Executive Officer, James Ward-Lilley, said:

"We have made a good start to the year and see the performance from our in-market business tracking as expected. We are making significant progress with our pipeline with a broad series of news flow anticipated for the rest of 2018, including our novel partnered projects (Ablynx ALX‌-0171), generic projects, late stage nebulised studies (VR647 Phase II, VR475 Phase III) and further Vectura enhanced programmes."

- Ends -

For more information, please contact:


Vectura Group plc

+44 (0)7471 352 720



David Ginivan - VP Corporate Communications

Julia Wilson - Director Investor Relations

+44 (0)7818 430 877


Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / Chris Welsh / Jessica Hodgson



About Vectura

Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.

Vectura has eight key inhaled, two non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Bayer, Chiesi, Almirall, Janssen, Dynavax and Tianjin KingYork.

Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products and through the development of high-quality generic alternatives to branded therapies.

For further information, please visit Vectura's website at